Tenet Healthcare Corporation $THC Stake Decreased by CreativeOne Wealth LLC

CreativeOne Wealth LLC trimmed its holdings in Tenet Healthcare Corporation (NYSE:THC) by 29.6% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 6,379 shares of the company’s stock after selling 2,680 shares during the quarter. CreativeOne Wealth LLC’s holdings in Tenet Healthcare were worth $1,295,000 at the end of the most recent reporting period.

Other hedge funds have also recently added to or reduced their stakes in the company. William B. Walkup & Associates Inc. bought a new position in shares of Tenet Healthcare in the third quarter worth $32,000. Canada Pension Plan Investment Board bought a new stake in shares of Tenet Healthcare during the second quarter valued at about $35,000. Westside Investment Management Inc. lifted its holdings in Tenet Healthcare by 100.0% in the third quarter. Westside Investment Management Inc. now owns 192 shares of the company’s stock worth $39,000 after purchasing an additional 96 shares during the period. Trust Co. of Vermont bought a new position in Tenet Healthcare in the 3rd quarter valued at about $41,000. Finally, Geneos Wealth Management Inc. increased its stake in Tenet Healthcare by 50.9% during the 2nd quarter. Geneos Wealth Management Inc. now owns 264 shares of the company’s stock valued at $46,000 after buying an additional 89 shares during the period. Institutional investors own 95.44% of the company’s stock.

Insider Activity at Tenet Healthcare

In related news, Director Nadja West sold 2,178 shares of the business’s stock in a transaction that occurred on Monday, December 15th. The shares were sold at an average price of $197.47, for a total transaction of $430,089.66. Following the transaction, the director directly owned 28,480 shares of the company’s stock, valued at approximately $5,623,945.60. The trade was a 7.10% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, EVP Thomas W. Arnst sold 24,000 shares of the stock in a transaction that occurred on Monday, March 2nd. The stock was sold at an average price of $234.04, for a total transaction of $5,616,960.00. Following the completion of the sale, the executive vice president owned 8,012 shares of the company’s stock, valued at approximately $1,875,128.48. The trade was a 74.97% decrease in their position. The SEC filing for this sale provides additional information. Over the last three months, insiders have sold 42,195 shares of company stock valued at $9,823,406. Corporate insiders own 0.81% of the company’s stock.

Tenet Healthcare Stock Performance

Shares of Tenet Healthcare stock opened at $237.30 on Wednesday. The stock has a market cap of $20.64 billion, a PE ratio of 15.32, a price-to-earnings-growth ratio of 1.19 and a beta of 1.39. Tenet Healthcare Corporation has a 12 month low of $109.82 and a 12 month high of $247.21. The company has a quick ratio of 1.68, a current ratio of 1.76 and a debt-to-equity ratio of 2.18. The business has a fifty day simple moving average of $211.66 and a 200-day simple moving average of $203.29.

Tenet Healthcare (NYSE:THC) last announced its quarterly earnings data on Wednesday, February 11th. The company reported $4.70 earnings per share (EPS) for the quarter, topping the consensus estimate of $4.08 by $0.62. Tenet Healthcare had a return on equity of 26.33% and a net margin of 6.60%.The firm had revenue of $5.53 billion during the quarter, compared to the consensus estimate of $5.47 billion. During the same period in the prior year, the business earned $3.44 EPS. The business’s revenue for the quarter was up 8.9% on a year-over-year basis. Tenet Healthcare has set its FY 2026 guidance at 16.190-18.470 EPS. On average, sell-side analysts anticipate that Tenet Healthcare Corporation will post 12.24 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of brokerages have recently weighed in on THC. Morgan Stanley reaffirmed an “overweight” rating and issued a $260.00 price target on shares of Tenet Healthcare in a research note on Thursday, February 12th. Barclays boosted their target price on Tenet Healthcare from $240.00 to $257.00 and gave the stock an “overweight” rating in a report on Friday, February 13th. Weiss Ratings raised Tenet Healthcare from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Monday, December 29th. Wall Street Zen raised Tenet Healthcare from a “buy” rating to a “strong-buy” rating in a research note on Sunday, March 1st. Finally, Leerink Partners raised their target price on Tenet Healthcare from $255.00 to $264.00 and gave the company an “outperform” rating in a research note on Friday, February 20th. One research analyst has rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and three have assigned a Hold rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $247.67.

Tenet Healthcare Company Profile

Tenet Healthcare Corporation (NYSE: THC) is a diversified American healthcare services company that owns and operates acute care hospitals and a broad range of outpatient facilities. Its portfolio includes general acute-care hospitals, specialty hospitals, ambulatory surgery centers, urgent care and diagnostic imaging centers, and other ancillary service locations. Tenet’s operations are oriented around delivering inpatient and outpatient clinical care across multiple medical specialties, with an emphasis on surgical services, emergency care, and advanced diagnostics.

In addition to facility-based care, Tenet provides integrated services designed to support clinical operations and improve patient access and care coordination.